| OCULUS
INNOVATIVE SCIENCES ANNOUNCES REGULATORY APPROVAL BY THERAPEUTIC
PRODUCT DIRECTORATE TO MARKET COMPANY’S FIRST MICROCYN®-FORMULATED
PRODUCT IN CANADA
Dermacyn™ Wound Care is a
super-oxidized, non-toxic, non-irritating, and no-rinse dermal
wound irrigant
PETALUMA, CA-- (Nov. 1, 2004)—
Kim Kelderman, COO of Oculus Innovative Sciences, today announced
that the company has received regulatory approval from Therapeutic
Product Directorate, the Canadian federal authority that regulates
pharmaceutical drugs and medical devices for human use, to
market the company’s first Canadian product, Dermacyn™
Wound Care formulated with Microcyn® technology. Non-toxic,
non-bleach-based and pH-neutral, Dermacyn™ Wound Care
is a dermal wound irrigant that facilitates removal of wound
debris as it cleanses and debrides . It is sterile, pyrogen-free,
non-flammable and with an extended shelf life. Since it contains
no perfumes, tints or dyes it is also environmentally safe.
A pressure-spray nozzle provides for optimal irrigation pressure.
“ Dermacyn™ is certainly an
advance in wound management technology,“ said Kelderman.
“It has been shown to be successful in moistening, irrigating
and debriding acute and chronic dermal lesions such as stage
I-IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgical
wounds, first- and second-degree burns, abrasions and minor
irritations of the skin.”
The company has also received CE approval
for its Microcyn® technology under the European Medical
Device Directive 93/42/EEC this past spring and has been commercialized
in Mexico since 2003.
As well, the company introduced its first
U.S. product, Vetericyn™ Wound Spray for animals, with
the patented Microcyn® technology, this past July. Oculus
also received U.S Environmental Protection Agency approval
for its Microcyn® technology in October 2004.
The company expects to obtain additional
FDA approvals in the coming months, allowing expansion of
Microcyn® technology use in the U.S wound management
market.
Dermacyn™ Wound Care will be made
available in a variety of sizes to help address individual
wound care needs.
About Oculus
Oculus Innovative Sciences, headquartered in Petaluma, California,
is pioneering innovative life sciences and disruptive technologies
that globally re-define the disinfectant and antiseptic markets.
With a primary focus on anti-infective and wound management
technologies, the company has employees and operations in
Mexico, Europe and the U.S. and includes two wholly owned
subsidiaries, Oculus Technologies of Mexico, S.A. de C.V.,
and Oculus Innovative Sciences Netherlands B.V. Please visit
us at www.oculusis.com.
Forward-Looking
Statements
This press release contains forward-looking statements that
involve risks and uncertainties. These forward-looking statements
relate to, among other things, plans and timing for the introduction
of our products, statements about future market conditions,
supply and demand conditions, revenues, gross margins, operating
expenses, profits and other expectations, intentions and plans
contained in this press release that are not historical fact.
Our expectations as expressed in this press release depend
upon our ability to develop, manufacture and supply products
that meet defined specifications. When used in this press
release, the words “plan,” “expect,”
“believe,” and similar expressions generally identify
forward-looking statements. These statements reflect our current
expectations. They are subject to a number of risks and uncertainties,
including, but not limited to, changes in technology and changes
in the health sciences market. In light of the many risks
and uncertainties surrounding this market, you should understand
that we cannot assure you that the forward-looking statements
contained in this press release will be realized.
(Download
PDF: 92 KB)
|
